Products

Earnings
API

Get in Touch

Contact Us
X (Twitter)
LinkedIn

Resources

Disclaimer: CapyFin provides financial data and AI analysis for informational purposes only and does not provide investment advice or recommendations. Real-time data and AI outputs may be inaccurate, incomplete, delayed, or contain errors or hallucinations. Investing involves risk, including loss of principal. The service is provided “as is” and we disclaim liability to the fullest extent permitted by law. See our Terms of Service and Privacy Policy.

Zura Bio Fiscal Q4 2024 Earnings Report - CapyFin

Zura Bio

ZURA · NASDAQ🇺🇸

View Company

Overview Earnings

Dividends Seasonality Metrics

Q4 2025 -9.52%Q2 2025 +6.87%Q1 2025 -7.57%Q3 2024 -1.68%Q4 2024 +3.95%Q2 2024 -3.56%Q1 2024 -0.64%Q4 2023 +22.84%Q3 2023 +2.80%Q2 2023 -0.58%Q1 2023 -25.98%Q4 2022 -1.84%Q3 2022 Q2 2022 Q1 2022

Nov 07, 2024

•

Sep 30, 2024

Zura Bio Q4 2024 Earnings Report

Reported financial results for the third quarter of 2024 and recent corporate updates.

Key Takeaways

Zura Bio reported cash and cash equivalents of $188.2 million as of September 30, 2024. Research and development expenses were $6.0 million, and general and administrative expenses were $13.3 million for the third quarter of 2024. Net loss for the third quarter of 2024 was $22.9 million or $0.26 per share.

Made significant progress toward initiating the first Phase 2 trial of tibulizumab in SSc.

Working closely with a contract research organization (CRO) to begin trial readiness and prepare for site activation.

Selected a CRO to support the anticipated Phase 2 trial initiation for tibulizumab in HS in the second quarter of 2025.

Existing cash and cash equivalents and investments should be sufficient to support operations as currently planned through 2027.

Previous year: $99.8M